Ridgecrest Wealth Partners LLC Makes New $60,000 Investment in Senseonics Holdings, Inc. (NYSE:SENS)

Ridgecrest Wealth Partners LLC purchased a new position in Senseonics Holdings, Inc. (NYSE:SENS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 115,000 shares of the company’s stock, valued at approximately $60,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Cubist Systematic Strategies LLC boosted its holdings in shares of Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares during the period. FMR LLC lifted its position in Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after purchasing an additional 167,970 shares during the last quarter. Geode Capital Management LLC boosted its stake in Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares during the period. GSA Capital Partners LLP bought a new position in Senseonics in the 3rd quarter worth about $117,000. Finally, Symmetry Partners LLC acquired a new stake in shares of Senseonics in the third quarter valued at approximately $164,000. 12.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Senseonics news, CEO Timothy T. Goodnow bought 315,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was acquired at an average price of $0.31 per share, with a total value of $97,650.00. Following the completion of the transaction, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the acquisition, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at $941,960.72. This represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. StockNews.com started coverage on Senseonics in a report on Thursday, December 26th. They issued a “sell” rating for the company. HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of Senseonics in a report on Friday, November 15th.

Senseonics Trading Up 11.9 %

Shares of SENS opened at $1.13 on Monday. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The firm’s 50 day moving average is $0.50 and its 200-day moving average is $0.42. Senseonics Holdings, Inc. has a 12-month low of $0.25 and a 12-month high of $1.15.

Senseonics (NYSE:SENS) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The company had revenue of $4.26 million during the quarter, compared to the consensus estimate of $4.02 million. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. On average, sell-side analysts anticipate that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current year.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.